Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial Post author:admin Post published:March 12, 2025 Post category:uncategorized NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. You Might Also Like Variability in blood sugar response depends on individual’s metabolic health status June 4, 2025 Global childhood immunization coverage: Stalled progress and growing gaps July 15, 2024 Telehealth and primary care providers deliver effective diabetes treatment February 24, 2025